DePuy Synthes buys OrthoSpin and its robotic external fixation system

Johnson & Johnson’s (NYSE:JNJ) DePuy Synthes, through its Synthes GmbH affiliate, announced today that it acquired OrthoSpin.

Israel-based OrthoSpin develops a robot-assisted external fixation system for orthopedic treatments. The platform is used in conjunction with DePuy Synthes’ Maxframe multi-axial correction system, an external ring fixation system.

OrthoSpin received FDA clearance for its second generation, robotic, digitally-enabled G2 external fixation system in January of this year.

According to a news release, the acquisition highlights J&J’s efforts to advance innovation in medtech, with the company having kept tabs on OrthoSpin over the years.¬†OrthoSpin raised $3 million for the external fixation system in a July 2018 Series A funding round led by J&J. The company also led OrthoSpin’s Series B in March 2020.

DePuy Synthes introduced its Maxframe system in 2017 and recently launched new frame innovati…

Read more
  • 0

Orthospin wins FDA clearance for robotic external fixation system

OrthoSpin this week announced that it received FDA clearance for its second generation, robotic, digitally-enabled external fixation system for orthopedic treatments.

The G2 system makes pre-programmed adjustments automatically without patient involvement. It allows physicians to chart patient progress and immediately adjust treatment plans as needed.

“We are very excited to launch the Generation 2 OrthoSpin system,” active chairperson Assaf Dekel said in a news release. “We believe that robotic automation will revolutionize the hexapod bone deformity market and we are proud to play a part in this transformation.”

OrthoSpin’s G2 system is approved in Israel and can be used with the DePuy Synthes MaxFrame Multi-Axial Correction System.

Read more
  • 0